Drug intelligence / Profile preview

MGT-001

Development stage: Unknown
Lead developer: Metagen Therapeutics
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral, Rectal

Overview

MGT-001 is a fecal microbiota transplantation (FMT) therapy being developed by Metagen Therapeutics for the treatment of ulcerative colitis. The drug consists of donor-derived fecal microbiota intended to restore a healthy intestinal microbiome in patients with dysbiosis. It is being evaluated in two primary delivery formats: an endoscopic administration and an oral capsule formulation. The development is conducted in collaboration with Juntendo University, focusing on modulating the gut environment to induce clinical remission in inflammatory bowel disease. The program has completed the Advanced Medical Care B pathway in Japan and is currently in Phase 1/2 global clinical trials.

Targets

Intestinal microbiota composition and function

Beyond the preview

Go deeper on MGT-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MGT-001.

Explore the full profile